Increased expression of DLX2 correlates with advanced stage of gastric adenocarcinoma

Table 1 Relationship of distal-less homeobox 2 expression with clinicopathological features of gastric adenocarcinoma n (%)

Clinicopathological features	Cases	DLX2 expression		χ2test	P value
		Low	High
Age (yr)				0.954	0.329
< 60	69	46 (66.7)	23 (33.3)
≥ 60	60	35 (58.3)	25 (41.7)
Gender				1.989	0.158
Female	42	30 (71.4)	12 (28.6)
Male	87	51 (58.6)	36 (41.4)
Tumor size (cm)				11.518	0.001
< 5	68	52 (76.5)	16 (23.5)
≥ 5	61	29 (47.5)	32 (52.5)
Tumor location				2.335	0.506
Upper	14	10 (71.4)	4 (28.6)
Middle	20	14 (70.0)	6 (30.0)
Lower	84	52 (61.9)	32 (38.1)
Diffuse	11	5 (45.5)	6 (54.5)
Histologic differentiation				3.186	0.364
Well	16	11 (68.8)	5 (31.3)
Moderately	28	21 (75.0)	7 (25.0)
Poorly	74	42 (56.8)	32 (43.2)
Other	11	7 (63.6)	4 (36.4)
Depth of invasion				11.940	0.008
T1	28	24 (85.7)	4 (14.3)
T2	24	16 (66.7)	8 (33.3)
T3	58	28 (48.3)	30 (51.7)
T4	19	13 (68.4)	6 (31.6)
Lymph node metastasis				9.577	0.023
N0	69	50 (72.5)	19 (27.5)
N1	17	12 (70.6)	5 (29.4)
N2	25	11 (44.0)	14 (56.0)
N3	18	8 (44.4)	10 (55.6)
Distant metastasis				0.012	0.914
M0	120	76 (63.3)	44 (36.7)
M1	9	5 (55.6)	4 (44.4)
TNM stages				9.849	0.020
I	43	35 (81.4)	8 (18.6)
II	43	24 (55.8)	19 (44.2)
III	34	17 (50.0)	17 (50.0)
IV	9	5 (55.6)	4 (44.4)

DLX2: Distal-less homeobox 2.